Company:  TESARO, INC. (TSRO)
Form Type:  8-K
Filing Date:  1/8/2014 
CIK:  0001491576 
Address:  1000 WINTER STREET, SUITE 3300 
City, State, Zip:  WALTHAM, Massachusetts 02451 
Telephone:  (339) 970-0900 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.04 (-0.16%)  
Trade Time: 
Apr 24  
Market Cap: 
Description of Business
We are an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. We acquire, in-license and develop oncology product candidates and, if approved for marketing, we intend to commercialize these products globally. We have in-licensed and are currently developing three product candidates, rolapitant, niraparib and TSR-011, and in March 2014 we initiated our immuno-oncology platform strategy by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., or AnaptysBio, for the discovery and development of antibodies for specified immuno-oncology targets. � Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist currently in Phase 3 (oral formulation) and Phase 1 (intravenous, or IV, formulation) clinical trials for the prevention of chemotherapy induced nausea and vomiting, or CINV. In December 2013, we announced top-line results for two Phase 3 trials of rolapitant.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    Section 7 - Regulation FD Disclosure
      Item 7.01 Regulation FD Disclosure.
    Section 9 - Financial Statements and Exhibits
      Item 9.01 Financial Statements and ...
  EXHIBIT 99.1